Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease
Abstract
In order to establish whether positron emission tomography (PET) can identify metabolic changes in Alzheimer's disease at a presymptomatic stage, we have examined 24 asymptomatic at risk individuals from families with Alzheimer's disease. A significant reduction in global cerebral metabolic rate for glucose was found when compared with 16 age-matched controls. There was also a focal, parieto-temporal deficit similar to, although less extensive than, that found in 18 symptomatic individuals from familial Alzheimer's disease (FAD) pedigrees. Follow up of this cohort will establish whether these metabolic changes relate to a presymptomatic stage of the disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Case series suggest that abnormalities in glucose metabolism can be detected by PET before substantial impairment occurs in persons at risk for Alzheimer's disease.
“Case series suggest that abnormalities in glucose metabolism can be detected by PET before substantial impairment occurs in persons at risk for Alzheimer's disease [14][15][16]”
From Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the ε4 Allele for Apolipoprotein E (1996) · cites this paper as [16]
The citation lists haven’t been fetched yet
References 10 · Cited by 250
- Authors
- Kennedy, A. M., Frackowiak, R. S. J., Newman, S. K., Bloomfield, P. M., Seaward, J., Roques, P., Lewington, G., Cunningham, V. J., & Rossor, M. N.
- Affiliations
- Hammersmith Hospital (GB)
- St Mary's Hospital (GB)
- Corresponding author
- Rossor, Martin N.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 1995-02
- Volume
- 186
- Issue
- 1
- Pages
- 17-20
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2018724570
- Cited by
- 250
- References
- 10
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 1 · 2017: 4 · 2016: 8 · 2015: 4 · 2014: 7 · 2013: 8 · 2012: 10
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- familial Alzheimer's disease, brain glucose metabolism, preclinical Alzheimer's disease, positron emission tomography, early detection of Alzheimer's disease
- MeSH terms
- Adult, Aged, Alzheimer Disease, Female, Glucose, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Risk Factors, Tomography, Emission-Computed, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
